IGC Pharma, Inc.
IGC- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001326205
No open-market purchases or sales by IGC Pharma, Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $1.41M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in IGC Pharma, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −1 vs. Q2 2024
- Shares held
- 2.80M
- +946.4K (+51.0%) vs. Q2 2024
- Total value
- $1.19M
- +$388.7K (+48.3%) vs. Q2 2024
- New holders
- 3
- 9 more added
- Sold out
- 4
- 2 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IGC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 36 | $1.41M |
| Q1 2026 | 35 | $1.14M |
| Q4 2025 | 30 | $1.36M |
| Q3 2025 | 35 | $2.27M |
| Q2 2025 | 28 | $929.4K |
| Q1 2025 | 25 | $814.9K |
| Q4 2024 | 30 | $954.3K |
| Q3 2024 | 23 | $1.19M |
| Q2 2024 | 25 | $1.11M |
| Q1 2024 | 25 | $943.4K |
| Q4 2023 | 25 | $691.3K |
| Q3 2023 | 27 | $1.01M |
| Q2 2023 | 23 | $827.5K |
| Q1 2023 | 23 | $917.6K |
| Q4 2022 | 26 | $937.3K |
| Q3 2022 | 26 | $1.31M |
| Q2 2022 | 29 | $1.73M |
| Q1 2022 | 29 | $3.97M |
| Q4 2021 | 29 | $6.07M |
| Q3 2021 | 32 | $7.90M |
| Q2 2021 | 29 | $7.90M |
| Q1 2021 | 29 | $7.97M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding IGC Pharma, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 703,798 | $300.5K | 0.00% | +703,798 | New |
| Vanguard Group Inc | 645,166 | $275.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 562,969 | $240.4K | 0.00% | +133,142+31.0% | Added |
| State Street Corp | 165,307 | $70.6K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 123,060 | $53.0K | 0.00% | +76,563+164.7% | Added |
| Dearborn Partners LLC | 116,401 | $49.7K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 99,017 | $42.3K | 0.00% | +65,412+194.6% | Added |
| Fullcircle Wealth LLC | 103,443 | $41.9K | 0.02% | +103,443 | New |
| Northern Trust Corp | 71,027 | $30.3K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 65,541 | $28.0K | 0.00% | +46+0.1% | Added |
| Commonwealth Equity Services, LLC | 44,600 | $19.0K | 0.00% | +10,000+28.9% | Added |
| Truist Financial Corp | 36,667 | $15.7K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 21,409 | $9.14K | 0.00% | −708−3.2% | Reduced |
| Morgan Stanley | 17,757 | $7.58K | 0.00% | +16,897+1,964.8% | Added |
| Tower Research Capital LLC (TRC) | 10,496 | $4.48K | 0.00% | +2,478+30.9% | Added |
| Baader Bank INC | 10,533 | $3.17K | 0.00% | +10,533 | New |
| Geneos Wealth Management Inc. | 3,000 | $1.29K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 925 | $397 | 0.00% | +125+15.6% | Added |
| CIBC Private Wealth Group, LLC | 655 | $280 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 563 | $240 | 0.00% | +146+35.0% | Added |
| Caitlin John, LLC | 200 | $73 | 0.00% | 00.0% | Unchanged |
| DHJJ Financial Advisors, Ltd. | 80 | $35 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 1,012 | $0 | 0.00% | −1,000−49.7% | Reduced |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −152,376−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −22,060−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −36−100.0% | Sold out |
| Toronto Dominion Bank | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |